Acelyrin Inc (NASDAQ: SLRN)’s stock price has gone decline by 0.00 in comparison to its previous close of 2.79, however, the company has experienced a 3.72% increase in its stock price over the last five trading days. globenewswire.com reported 2025-03-13 that LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”).
Is It Worth Investing in Acelyrin Inc (NASDAQ: SLRN) Right Now?
The 36-month beta value for SLRN is also noteworthy at 0.94. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SLRN is 72.98M, and at present, short sellers hold a 5.89% of that float. The average trading volume of SLRN on March 20, 2025 was 2.21M shares.
SLRN’s Market Performance
SLRN stock saw an increase of 3.72% in the past week, with a monthly gain of 29.77% and a quarterly increase of -17.21%. The volatility ratio for the week is 3.33%, and the volatility levels for the last 30 days are 5.02% for Acelyrin Inc (SLRN). The simple moving average for the past 20 days is 4.74% for SLRN’s stock, with a -33.99% simple moving average for the past 200 days.
Analysts’ Opinion of SLRN
Many brokerage firms have already submitted their reports for SLRN stocks, with H.C. Wainwright repeating the rating for SLRN by listing it as a “Neutral.” The predicted price for SLRN in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on August 14, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see SLRN reach a price target of $13. The rating they have provided for SLRN stocks is “Overweight” according to the report published on July 08th, 2024.
Wells Fargo gave a rating of “Equal Weight” to SLRN, setting the target price at $11 in the report published on December 13th of the previous year.
SLRN Trading at 22.46% from the 50-Day Moving Average
After a stumble in the market that brought SLRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.52% of loss for the given period.
Volatility was left at 5.02%, however, over the last 30 days, the volatility rate increased by 3.33%, as shares surge +28.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.91% lower at present.
During the last 5 trading sessions, SLRN rose by +3.90%, which changed the moving average for the period of 200-days by -32.16% in comparison to the 20-day moving average, which settled at $2.66. In addition, Acelyrin Inc saw -11.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLRN starting from Kim Mina, who sale 17,986 shares at the price of $2.74 back on Mar 17 ’25. After this action, Kim Mina now owns 671,753 shares of Acelyrin Inc, valued at $49,354 using the latest closing price.
Murugan Amar, the Chief Legal Officer of Acelyrin Inc, sale 3,913 shares at $2.74 during a trade that took place back on Mar 17 ’25, which means that Murugan Amar is holding 121,587 shares at $10,737 based on the most recent closing price.
Stock Fundamentals for SLRN
Current profitability levels for the company are sitting at:
- -2022.04 for the present operating margin
- -0.32 for the gross margin
The net margin for Acelyrin Inc stands at -1592.8. The total capital return value is set at -0.63. Equity return is now at value -41.95, with -37.27 for asset returns.
Based on Acelyrin Inc (SLRN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -39.03.
Currently, EBITDA for the company is -381.53 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of 431.9. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.15.
Conclusion
In summary, Acelyrin Inc (SLRN) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
